troglitazone has been researched along with Congenital Myotonic Dystrophy in 2 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kono, S | 1 |
| Kashiwagi, K | 1 |
| Nagafuchi, S | 1 |
| Sekiguchi, N | 1 |
| Yamagata, A | 1 |
| Iwata, I | 1 |
| Furuya, H | 1 |
| Kato, M | 1 |
| Niho, Y | 1 |
1 review available for troglitazone and Congenital Myotonic Dystrophy
| Article | Year |
|---|---|
[Insulin resistance in myotonic dystrophy].
Topics: Chromans; Humans; Hyperinsulinism; Insulin Resistance; Insulin-Like Growth Factor I; Myotonic Dystro | 2002 |
1 other study available for troglitazone and Congenital Myotonic Dystrophy
| Article | Year |
|---|---|
Troglitazone not only reduced insulin resistance but also improved myotonia in a patient with myotonic dystrophy.
Topics: Adult; Chromans; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Myotonic Dystrophy; Thiazo | 1999 |